Malignant Tumors
Conditions
Brief summary
This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.
Interventions
Patients receiving immunotherapies such as immune checkpoint inhibitors. Immunotherapy can be administered as first-line or subsequent treatment, or as part of combination therapy, integrated with modalities such as surgery, chemotherapy, radiotherapy, and targeted therapy.
RADIATIONRadiation Therapy
Patients for whom radiotherapy is the primary or a significant component of their treatment. Radiotherapy may be administered with curative, adjuvant, or palliative intent, and can be given alone or in combination with surgery, chemotherapy, targeted therapy, immunotherapy, etc.
PROCEDURERadical surgery
Patients undergoing curative tumor resection as their primary treatment modality. Surgery may be performed with or without neoadjuvant/adjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Sponsors
Nanfang Hospital, Southern Medical University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntarily sign the informed consent form. 2. Treated at Nanfang Hospital, Southern Medical University between January 2017 and December 2025. 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2. 4. Availability of surplus routinely discarded clinical tumor tissue samples (biopsy specimens or pathological sections) or blood samples for assays such as sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry.
Exclusion criteria
Patients deemed by the investigator to be unsuitable for participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | From date of treatment initiation until date of death or last follow-up, assessed up to 5 years. | The time from the start of treatment to death from any cause. Patients who are alive at the last follow-up are censored. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Survival (PFS) | From date of treatment initiation until date of progression or death, assessed up to 5 years. | The time from the start of treatment to the first documented disease progression (per RECIST criteria) or death from any cause, whichever occurs first. |
| Pathological Complete Response (pCR) | At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy. | The absence of residual invasive cancer in the resected tumor specimen and lymph nodes after neoadjuvant therapy, as determined by histopathological evaluation. |
| Major Pathologic Response (MRP) | At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy. | The presence of ≤10% residual viable tumor cells in the resected tumor specimen after neoadjuvant therapy, assessed by pathological examination. |
Countries
China
Contacts
CONTACTWei Wang Wang
Outcome results
None listed